NASDAQ:IMUX Immunic (IMUX) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free IMUX Stock Alerts $1.27 +0.03 (+2.42%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.2850-Day Range$1.18▼$1.5352-Week Range$0.95▼$3.11Volume153,824 shsAverage Volume224,860 shsMarket Capitalization$114.40 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immunic alerts: Email Address Immunic MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside569.3% Upside$8.50 Price TargetShort InterestHealthy3.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.98) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.37 out of 5 starsMedical Sector525th out of 925 stocksPharmaceutical Preparations Industry246th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingImmunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunic has only been the subject of 1 research reports in the past 90 days.Read more about Immunic's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.13% of the outstanding shares of Immunic have been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Immunic has recently decreased by 2.08%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmunic does not currently pay a dividend.Dividend GrowthImmunic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMUX. Previous Next 3.2 News and Social Media Coverage News SentimentImmunic has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Immunic this week, compared to 2 articles on an average week.Search Interest7 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Immunic is held by insiders.Percentage Held by Institutions51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunic's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immunic are expected to grow in the coming year, from ($0.98) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunic is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunic is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunic has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immunic's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Immunic Stock (NASDAQ:IMUX)Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Read More IMUX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUX Stock News HeadlinesMay 10, 2024 | markets.businessinsider.comHold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial OutlookMay 9, 2024 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call TranscriptMay 11, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 9, 2024 | finance.yahoo.comWe Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth CarefullyMay 8, 2024 | msn.comIMUX Stock Earnings: Immunic Misses EPS for Q1 2024May 8, 2024 | proactiveinvestors.comImmunic advances ‘potentially groundbreaking' MS therapy vidofludimus calcium during Q1May 8, 2024 | prnewswire.comImmunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | msn.comImmunic Q1 2024 Earnings PreviewMay 11, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.May 6, 2024 | prnewswire.comImmunic to Participate in Investor and Scientific Conferences in MayMay 3, 2024 | benzinga.comImmunic Stock (NASDAQ:IMUX), Quotes and News SummaryMay 1, 2024 | prnewswire.comImmunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateApril 30, 2024 | proactiveinvestors.comImmunic publishes extended data from Phase 2 MS trial in peer-reviewed journalApril 30, 2024 | prnewswire.comImmunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationApril 29, 2024 | finance.yahoo.comImmunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial roleApril 19, 2024 | finance.yahoo.comImmunic, Inc. (IMUX)April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)April 12, 2024 | morningstar.comImmunic Inc IMUXApril 5, 2024 | msn.comBrookline Capital starts Immunic at buy, cites MS drug candidateApril 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)April 4, 2024 | finance.yahoo.comWith 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investorsApril 4, 2024 | finance.yahoo.comImmunic to Host MS R&D Day and Participate in Investor Conferences in AprilMarch 20, 2024 | marketwatch.comImmunic Gets Allowance for Vidofludimus Calcium Patent ApplicationMarch 20, 2024 | proactiveinvestors.comImmunic granted patent for specific polymorph of vidofludimus calcium in USMarch 20, 2024 | prnewswire.comImmunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United StatesMarch 18, 2024 | proactiveinvestors.comImmunic CMO discusses complexities of multiple sclerosis to mark MS Awareness MonthMarch 7, 2024 | prnewswire.comImmunic to Participate in Investor and Scientific Conferences in MarchSee More Headlines Receive IMUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/11/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMUX CUSIPN/A CIK1280776 Webwww.immunic-therapeutics.com Phone(332) 255-9818Fax858-673-6843Employees77Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+569.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-161.82% Return on Assets-118.57% Debt Debt-to-Equity RatioN/A Current Ratio5.09 Quick Ratio2.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book1.37Miscellaneous Outstanding Shares90,080,000Free Float87,377,000Market Cap$114.40 million OptionableOptionable Beta1.93 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Duane D. Nash J.D. (Age 53)M.B.A., M.D., Executive Chairman Comp: $433.4kDr. Daniel Vitt Ph.D. (Age 56)CEO, President & Director Comp: $728.4kMr. Glenn Whaley CPA (Age 56)Chief Financial Officer Comp: $522.21kDr. Andreas Muehler M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $599.57kDr. Hella Kohlhof (Age 51)Chief Scientific Officer Jessica BreuHead of Investor Relations & CommunicationsMr. Inderpal Singh (Age 58)General Counsel Mr. Patrick Walsh (Age 41)Chief Business Officer More ExecutivesKey CompetitorsCartesian TherapeuticsNASDAQ:RNACAbeona TherapeuticsNASDAQ:ABEOVistagen TherapeuticsNASDAQ:VTGNCoya TherapeuticsNASDAQ:COYAKaryopharm TherapeuticsNASDAQ:KPTIView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,703,047 shares on 5/10/2024Ownership: 3.768%Acadian Asset Management LLCSold 319,343 shares on 5/10/2024Ownership: 0.266%Summit Trail Advisors LLCBought 18,600 shares on 4/23/2024Ownership: 0.021%Sierra Summit Advisors LLCBought 324,829 shares on 2/22/2024Ownership: 0.719%Glenn WhaleyBought 5,000 shares on 5/15/2023Total: $8,750.00 ($1.75/share)View All Insider TransactionsView All Institutional Transactions IMUX Stock Analysis - Frequently Asked Questions Should I buy or sell Immunic stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMUX shares. View IMUX analyst ratings or view top-rated stocks. What is Immunic's stock price target for 2024? 2 Wall Street analysts have issued 12-month price objectives for Immunic's shares. Their IMUX share price targets range from $7.00 to $10.00. On average, they predict the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 569.3% from the stock's current price. View analysts price targets for IMUX or view top-rated stocks among Wall Street analysts. How have IMUX shares performed in 2024? Immunic's stock was trading at $1.50 on January 1st, 2024. Since then, IMUX shares have decreased by 15.3% and is now trading at $1.27. View the best growth stocks for 2024 here. When is Immunic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our IMUX earnings forecast. How were Immunic's earnings last quarter? Immunic, Inc. (NASDAQ:IMUX) released its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.03. What other stocks do shareholders of Immunic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and Who are Immunic's major shareholders? Immunic's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.77%), Acadian Asset Management LLC (0.27%) and Summit Trail Advisors LLC (0.02%). Insiders that own company stock include Andreas Muehler, Daniel Vitt, Duane Nash, Glenn Whaley and Joerg Neermann. View institutional ownership trends. How do I buy shares of Immunic? Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMUX) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
